GSK licensed rights to GSK'227 outside China, Hong Kong, Macao, and Taiwan in December 2023 for $185 million upfront and another $1.525 billion is potential milestone payments. A few weeks earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback